Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy

被引:9
作者
Chan, Wei Yen [1 ,2 ]
Lee, Jenny H. [1 ,3 ]
Stewart, Ashleigh [1 ,2 ]
Diefenbach, Russell J. [1 ,2 ]
Gonzalez, Maria [2 ]
Menzies, Alexander M. [2 ,4 ,5 ]
Blank, Christian [6 ,7 ,8 ]
Scolyer, Richard A. [2 ,4 ,9 ,10 ,11 ]
Long, Georgina V. [2 ,4 ,5 ,9 ]
Rizos, Helen [1 ,2 ]
机构
[1] Macquarie Univ, Fac Med Hlth & Human Sci, Sydney, NSW, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[3] Chris Obrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[5] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia
[6] Netherlands Canc Inst NKI, Dept Med Oncol, Amsterdam, Netherlands
[7] Leiden Univ, Med Ctr LUMC, Dept Med Oncol, Leiden, Netherlands
[8] Univ Clin Regensburg UKR, Dept Hematol & Med Oncol, Regensburg, Germany
[9] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[10] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia
[11] NSW Hlth Pathol, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
Circulating tumour DNA; Stage III melanoma; Neoadjuvant therapy; Recurrence risk; SURVIVAL; ADJUVANT; IPILIMUMAB;
D O I
10.1186/s13046-024-03153-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeoadjuvant therapy improves recurrence-free survival (RFS) in resectable stage III cutaneous melanoma. However, accurately predicting individual recurrence risk remains a significant challenge. We investigated circulating tumour DNA (ctDNA) as a biomarker for recurrence in measurable stage IIIB/C melanoma patients undergoing neoadjuvant immunotherapy. MethodsPlasma samples were collected pre-neoadjuvant treatment, pre-surgery and/or six weeks post-surgery from 40 patients enrolled in the OpACIN-neo and PRADO clinical trials. Patients received two cycles of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) before surgery. Cell free DNA (cfDNA) underwent unbiased pre-amplification followed by tumour-informed mutation detection using droplet digital polymerase chain reaction (ddPCR) with the Bio-Rad QX600 PCR system. ResultsPre-treatment ctDNA was detectable in 19/40 (48%) patients. Among these, 17/19 (89%) zero-converted within six weeks of surgery and none recurred. Positive ctDNA post-surgery (N = 4), irrespective of pre-treatment ctDNA status, was 100% predictive of recurrence (sensitivity 44%, specificity 100%). Furthermore, ctDNA cleared prior to surgery in 7/9 (78%) patients who did not recur, warranting further investigation into ctDNA-guided surgical management. ConclusionPost-surgery ctDNA positivity and zero-conversion are highly predictive of recurrence, offering a window for personalised modification of adjuvant therapy.
引用
收藏
页数:9
相关论文
共 50 条
[41]   Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade [J].
Johannet, Paul ;
Liu, Wenke ;
Fenyo, David ;
Wind-Rotolo, Megan ;
Krogsgaard, Michelle ;
Mehnert, Janice M. ;
Weber, Jeffrey S. ;
Zhong, Judy ;
Osman, Iman .
CLINICAL CANCER RESEARCH, 2022, 28 (18) :4121-4130
[42]   Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer [J].
Tie, Jeanne ;
Cohen, Joshua D. ;
Wang, Yuxuan ;
Christie, Michael ;
Simons, Koen ;
Lee, Margaret ;
Wong, Rachel ;
Kosmider, Suzanne ;
Ananda, Sumitra ;
McKendrick, Joseph ;
Lee, Belinda ;
Cho, Jin Hee ;
Faragher, Ian ;
Jones, Ian T. ;
Ptak, Janine ;
Schaeffer, Mary J. ;
Silliman, Natalie ;
Dobbyn, Lisa ;
Li, Lu ;
Tomasetti, Cristian ;
Papadopoulos, Nicholas ;
Kinzler, Kenneth W. ;
Vogelstein, Bert ;
Gibbs, Peter .
JAMA ONCOLOGY, 2019, 5 (12) :1710-1717
[43]   Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer [J].
Cohen, Ryan ;
Beasley, Aaron ;
McCoy, Melanie ;
Platell, Cameron ;
Meehan, Katie ;
Gray, Elin ;
Fuller, Kathy .
ANZ JOURNAL OF SURGERY, 2023, 93 (10) :2473-2480
[44]   Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients [J].
Henriksen, Tenna Vesterman ;
Reinert, Thomas ;
Rasmussen, Mads Heilskov ;
Demuth, Christina ;
Love, Uffe Schou ;
Madsen, Anders Husted ;
Gotschalck, Kare Andersson ;
Iversen, Lene Hjerrild ;
Andersen, Claus Lindbjerg .
MOLECULAR ONCOLOGY, 2022, 16 (20) :3654-3665
[45]   C-Reactive Protein and Lymphocyte-to-Monocyte Ratio Predict Recurrence in Stage III Melanoma Patients with Microscopic Sentinel Lymph Node Metastasis [J].
Schildbach, Viktoria Anna Sophie ;
Horn, Susanne ;
Hidalgo-Gadea, Guillermo ;
Johannis, Wibke ;
Mauch, Cornelia ;
Franklin, Cindy .
CANCERS, 2023, 15 (03)
[46]   Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma [J].
Hoshimoto, Sojun ;
Faries, Mark B. ;
Morton, Donald L. ;
Shingai, Tatsushi ;
Kuo, Christine ;
Wang, He-jing ;
Elashoff, Robert ;
Mozzillo, Nicola ;
Kelley, Mark C. ;
Thompson, John F. ;
Lee, Jeffrey E. ;
Hoon, Dave S. B. .
ANNALS OF SURGERY, 2012, 255 (02) :357-362
[47]   Outcome of Patients With Early-Stage Mismatch Repair Deficient Colorectal Cancer Receiving Neoadjuvant Immunotherapy: A Systematic Review [J].
Chakrabarti, Sakti ;
Grewal, Udhayvir Singh ;
Vora, Kruti Bhagirath ;
Parikh, Aparna Raj ;
Almader-Douglas, Diana ;
Mahipal, Amit ;
Sonbol, Mohamad B. .
JCO PRECISION ONCOLOGY, 2023, 7
[48]   Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study [J].
Syeda, Mahrukh M. ;
Wiggins, Jennifer M. ;
Corless, Broderick C. ;
Long, Georgina, V ;
Flaherty, Keith T. ;
Schadendorf, Dirk ;
Nathan, Paul D. ;
Robert, Caroline ;
Ribas, Antoni ;
Davies, Michael A. ;
Grob, Jean Jacques ;
Gasal, Eduard ;
Squires, Matthew ;
Marker, Mahtab ;
Garrett, James ;
Brase, Jan C. ;
Polsky, David .
LANCET ONCOLOGY, 2021, 22 (03) :370-380
[49]   Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients [J].
Herbreteau, Guillaume ;
Vallee, Audrey ;
Knol, Anne-Chantal ;
Theoleyre, Sandrine ;
Quereux, Gaelle ;
Frenard, Cecile ;
Varey, Emilie ;
Hofman, Paul ;
Khammari, Amir ;
Dreno, Brigitte ;
Denis, Marc G. .
CANCERS, 2020, 12 (07) :1-13
[50]   Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment [J].
Dennis A Revicki ;
Alfons JM van den Eertwegh ;
Paul Lorigan ;
Celeste Lebbe ;
Gerald Linette ;
Christian H Ottensmeier ;
Shima Safikhani ;
Marianne Messina ;
Axel Hoos ;
Samuel Wagner ;
Srividya Kotapati .
Health and Quality of Life Outcomes, 10